ClinicalTrials.gg
RecruitingNCT07205445Updated Oct 26, 2026

Tensi+ European Post-Market Clinical Follow-Up

An observational study in Overactive Bladder, sponsored by Stimuli Technology. Recruiting at 17 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Stimuli Technology · Observational

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 8 months later.
Updated Oct 26, 2026Site recruiting status changedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Urinary Bladder, Overactive with a site in Italy — 3 open to participants now, 3 under way, none of them phase 3. Urinary Bladder, Overactive · Italy.

Started
2025
with 1 other
Observational
5 of 30
2 open now
Registered
28th of 30
by date

Among the 30 studies in Urinary Bladder, Overactive with a site in Italy, this one is one of 2 that started in 2025, is one of 5 observational ones, and was the 28th registered.

Urinary Bladder, Overactive

861 studies on the registry are indexed under Urinary Bladder, Overactive; 128 are open to participants now.

Browse Urinary Bladder, Overactive studies →

Open to participants now

3 of the 30 studies in Urinary Bladder, Overactive with a site in Italy are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 75 Urinary Bladder, Overactive studies recruiting now, 45 (60%) set no upper age limit and 16 (21%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Urinary Bladder, Overactive with a site in Italy, or all of them as a file.
02

Study summary

Tensi+ (Stimuli Technology, Boulogne Billancourt, France) is a newly released, medical transcutaneous-posterior tibial nerve stimulation (TC-pTNS) device marketed for overactive bladder (OAB) management. Preliminary studies have shown a favorable safety and efficacy profile. The goal of the present registry is to collect data among an important number of patients to assess the efficacy, safety and potential predictive factors of success in a current clinical setting over a total period of 1 year.

03

Conditions studied

  • Overactive Bladder

Keywords

  • Urology
  • TENS
  • Overactive bladder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Age ≥ 18 years Overactive bladder symptoms

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Patients suffering from idiopathic or neurological overactive bladder

Exclusion criteria

Exclusion Criteria:

  • Patients with pacemaker, defibrillator, or any other electronic implant;
  • Patients with metal implant near the stimulation area;
  • Pregnant women;
  • People suffering from ankle joint problems, swollen ankles or a dermatological condition or damaged skin in the area where the electrodes are to be placed;
  • Patient with cognitive impairment;
  • Inability to complete a voiding diary;
  • No social security cover (for applicable countries).
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Interventions

  • DeviceTensi+

    Tensi+ (Stimuli Technology, Boulogne Billancourt, France) is a newly released, medical transcutaneous-posterior tibial nerve stimulation (TC-pTNS) device marketed for overactive bladder (OAB) management.

06

What researchers measure

Primary outcomes

  1. Subjective improvement

    The Patient Global Impression of Improvement (PGI-I) uses a 7-point scale, where post-treatment condition is rated as follows: 1. = Very much better 2. = Much better 3. = A little better 4. = No change 5. = A little worse 6. = Much worse 7. = Very much worse. For analysis, patients with a PGI-I score of 1, 2, or 3 are typically considered responders, reflecting meaningful improvement.

    Time frame: 3 and 12 months

Secondary outcomes

  1. Patient-reported Outcomes Measures (PROMs)

    Urinary symptoms by filling up International Consultation on Incontinence Questionnaire - Female Lower Urinary Tract Symptoms (ICIQ-FLUTS) which is a questionnaire intended to assess female storage, voiding and incontinence symptoms. Lower scores are typically associated with reduced symptom severity.

    Time frame: 0; 3 and 12 months

  2. Patient-reported Outcomes Measures (PROMs)

    Urinary symptoms by filling up International Consultation on Incontinence Questionnaire - Male Lower Urinary Tract Symptoms (ICIQ-MLUTS) which is a questionnaire intended to assess male storage, voiding and incontinence symptoms. Lower scores are typically associated with reduced symptom severity.

    Time frame: 0; 3 and 12 months

  3. Quality of life measures

    By filling up International Consultation on Incontinence Questionnaire - OAB quality of life (ICIQ-OABqol) which is a questionnaire evaluating quality of life in patients with overactive bladder. Lower scores are typically associated with improved quality of life.

    Time frame: 0; 3 and 12 months

Other outcomes

  1. Patient-reported Outcomes Measures (PROMs)

    By filling up International Consultation on Incontinence Questionnaire - Bowel (ICIQ-B) which is a questionnaire for evaluating symptoms of anal incontinence. Lower scores are typically associated with reduced symptom severity.

    Time frame: 0; 3 and 12 months

  2. Evaluation of voiding frequency

    Evaluation of daytime voiding frequency averaged over three days from bladder diary entries

    Time frame: 0; 3 and 12 months

  3. Evaluation of urgency

    Evaluation of daily urgency episodes averaged over three days from bladder diary entries

    Time frame: 0; 3 and 12 months

  4. Evaluation of nocturia

    Evaluation of nocturia episodes averaged over three days from bladder diary entries

    Time frame: 0; 3 and 12 months

  5. Evaluation of urgency urinary incontinence

    Evaluation of urgency urinary incontinence episodes averaged over three days from bladder diary entries

    Time frame: 0; 3 and 12 months

  6. Evaluation of adverse events

    Patients will be asked whether they experienced any adverse events during treatment. Patient responses will be collected and described qualitatively, enabling the identification of the types of adverse events reported as well as the frequency of their occurrence.

    Time frame: 3 and 12 months

07

Study locations

12 of 17 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Oct 2028, 43 months after the start.

Of 59 observational studies under Urinary Bladder, Overactive, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 45. This study's planned 43 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: primary completion Oct 2027 → Oct 2028 and completion Oct 2027 → Oct 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2025
First posted
Oct 3, 2025
StartActual
Feb 27, 2025
Primary completionEst.
Oct 1, 2028was Oct 2027
CompletionEst.
Oct 1, 2028was Oct 2027
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
7 sites changed recruiting status (7 now recruiting)
Show 7 sites
  • Nuova Villa Esther · Avellino, ItalyNot yet recruiting→Recruiting
  • Hesperia Hospital · Modena, ItalyNot yet recruiting→Recruiting
  • Santa Maria la Gruccia Hospital · Montevarchi, ItalyNot yet recruiting→Recruiting
  • Casa di Cura Villa Stuart · Roma, ItalyNot yet recruiting→Recruiting
  • Villa Salaria Hospital · Roma, ItalyNot yet recruiting→Recruiting
  • Azienda Ospedaliero Universitaria Sant'Andrea · Roma, ItalyNot yet recruiting→Recruiting
  • Clinica Nuova Villa Claudia · Roma, ItalyNot yet recruiting→Recruiting
Oct 26, 2026
Primary completion
Oct 1, 2027→Oct 1, 2028
Oct 22, 2026
Study completion
Oct 1, 2027→Oct 1, 2028
Oct 22, 2026
Title
Tensi+ European Registry→Tensi+ European Post-Market Clinical Follow-Up
Oct 22, 2026
Show all 2 updates
  1. Oct 26, 2026
    8 sites changed recruiting status (8 now recruiting)
    Show 8 sites
    • Nuova Villa Esther · Avellino, ItalyNot yet recruiting→Recruiting
    • Hesperia Hospital · Modena, ItalyNot yet recruiting→Recruiting
    • Santa Maria la Gruccia Hospital · Montevarchi, ItalyNot yet recruiting→Recruiting
    • Casa di Cura Villa Stuart · Roma, ItalyNot yet recruiting→Recruiting
    • Villa Salaria Hospital · Roma, ItalyNot yet recruiting→Recruiting
    • Azienda Ospedaliero Universitaria Sant'Andrea · Roma, ItalyNot yet recruiting→Recruiting
    • Azienda Ospedaliero Universitaria Sant'Andrea · Roma, ItalyNot yet recruiting→Recruiting
    • Clinica Nuova Villa Claudia · Roma, ItalyNot yet recruiting→Recruiting
  2. Oct 22, 2026
    Primary completion Oct 1, 2027→Oct 1, 2028
    Study completion Oct 1, 2027→Oct 1, 2028
    Title Tensi+ European Registry→Tensi+ European Post-Market Clinical Follow-Up
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07205445
Lead sponsor
Stimuli Technology
Responsible party
Sponsor
First posted
Oct 3, 2025
Start date
Feb 27, 2025
Primary completion
Oct 1, 2028 (estimated)
Completion
Oct 1, 2028 (estimated)
Last update
Oct 26, 2026

Study contacts

Akshaya Mariadassou
Contact
a.mariadassou@stimuli-technology.com
+331 84 60 48 25
Sarah Todeschini
Contact
s.todeschini@stimuli-technology.com
+331 84 60 48 25

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion